The Potential Role for Protein-Conjugate Pneumococcal Vaccine in Adults: What Is the Supporting Evidence?
Open Access
- 2 February 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 52 (5), 633-640
- https://doi.org/10.1093/cid/ciq207
Abstract
Vaccination with protein-conjugate pneumococcal vaccine (PCV) provides children with extraordinary protection against pneumococcal disease, although the protective effect may be blunted by the emergence of replacement strains. Studies in adults have compared PCV with pneumococcal polysaccharide vaccine (PPV) using surrogate markers of protection, namely, serum anticapsular IgG antibody and opsonic activity. Results suggest that PCV is at least as effective as PPV for the strains covered, but a definitive and consistent advantage has not been demonstrated. Unfortunately, persons who are most in need of vaccine do not respond as well as otherwise healthy adults to either vaccine. Newer formulations of PCV will protect against the most prevalent of the current replacement strains, but replacement strains will create a moving target for PCVs. Unless an ongoing trial comparing 13-valent PCV with placebo (not to PPV) demonstrates a clearly better effect than that seen in the past with PPV, cost-effectiveness considerations are likely to prevent widespread use of PCV in adults.This publication has 38 references indexed in Scilit:
- Nasopharyngeal Carriage ofStreptococcus pneumoniaeShortly before Vaccination with a Pneumococcal Conjugate Vaccine Causes Serotype‐Specific Hyporesponsiveness in Early InfancyThe Journal of Infectious Diseases, 2010
- A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected AdultsThe New England Journal of Medicine, 2010
- The Immunogenicity of 7‐Valent Pneumococcal Conjugate Vaccine versus 23‐Valent Polysaccharide Vaccine in Adults Aged 50–80 YearsClinical Infectious Diseases, 2009
- Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Alaska Native Adults 55–70 Years of AgeClinical Infectious Diseases, 2009
- Temporal Trends of Antimicrobial Resistance and Clonality of Invasive Streptococcus pneumoniae Isolates in Finland, 2002 to 2006Antimicrobial Agents and Chemotherapy, 2009
- Initial and Subsequent Response to Pneumococcal Polysaccharide and Protein‐Conjugate Vaccines Administered Sequentially to Adults Who Have Recovered from Pneumococcal PneumoniaThe Journal of Infectious Diseases, 2008
- Comparison of Pneumococcal Conjugate Polysaccharide and Free Polysaccharide Vaccines in Elderly Adults: Conjugate Vaccine Elicits Improved Antibacterial Immune Responses and Immunological MemoryClinical Infectious Diseases, 2008
- A Randomized, Double-Blind Trial of Pneumococcal Vaccination in Adult Allogeneic Stem Cell Transplant Donors and RecipientsClinical Infectious Diseases, 2007
- Efficacy of Pneumococcal Vaccine in High-Risk PatientsThe New England Journal of Medicine, 1986
- Antibody Response to Pneumococcal Vaccination in Children Younger than Five Years of AgeThe Journal of Infectious Diseases, 1983